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Abstract
COVID-19 is a global health emergency that originated in Wuhan, China, in December 2019. It
was declared a pandemic on March 11, 2020, and since then has affected more than 53,507,282
individuals and claimed the lives of more than 1,305,164 around the globe. It is a respiratory virus
transmitted from person to person through airborne aerosols and droplets from infected individuals
and direct contact with infected surfaces. Numerous factors, such as socioeconomic status,
population density, pre-existing health conditions, and lack of health insurance, have contributed
to the disproportionate impact of COVID-19 among certain demographic groups. The COVID-19
impact ranges from family disruptions, school closures, business closures, economic impact,
international travel, and trade disruptions. COVID-19 is still evolving as new evidence is being
identified. Preventive measures, such as using personal protective equipment (PPE), hand hygiene,
social distancing, and avoiding large group gatherings, have been shown to help reduce the spread
of COVID-19. With remdesivir being the only approved treatment of COVID-19, supportive
treatments have been implemented to help the patient with moderate to severe symptoms while
efforts for vaccine production and availability are still in progress. A national and global approach
to preventive measures is recommended with increased healthcare access, especially to high-risk
populations, and expanded educational awareness for improved population health. Healthcare
leaders, government, and private healthcare agencies, policymakers, and legislators are urged to
adopt these recommendations to improve the COVID-19 pandemic response and be prepared for
future health emergencies.
Keywords: COVID-19, Pandemic, Preventive measures, supportive care and treatment, vaccine,
recommendations.
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COVID-19: Best Practices and the Way Forward
The Coronavirus disease (COVID-19) has had a tremendous impact on global health
since identified in Wuhan, China, in December 2019. Since its detection, the health effects of
contracting COVID-19 have changed the way individuals, families, communities, and entire
countries are forced to live and function. During this period of adjustment to the COVID-19
restrictions, new knowledge about the virus pandemic evolves.
Disparities have also affected the severity and impact of the COVID-19 on specific
demographic groups, with a disproportionate burden of illness and death suffered by race,
ethnicity, region, and income (Centers for Disease and Control and Prevention (CDC), 2020c). In
September 2020, the CDC reported that the black or African Americans were five times as likely
and Latinos eight times as likely to die from COVID-19 related complications than their white
non-Hispanic peers (CDC, 2020c). Numerous factors include socioeconomics, population
density, pre-existing health conditions, and lack of health insurance, which places these
vulnerable populations at a disproportionately high risk of contracting and dying from COVID19.
There is a need for healthcare providers to develop strategies and best practices to
improve the health and wellness of individuals, families, and communities devastated by this
virus. Such practices include but are not limited to the availability of personal protective
equipment (PPE), maintaining social distancing, contact tracing, equitable access to testing
methods, and treatments. The COVID-19 pandemic has affected the local, state, national, and
international world differently. As of November 15, 2020, the World Health Organization
(WHO) reported an estimate of 53,507,282 confirmed cases of COVID-19, with 1,305,164
deaths, and the death rate is at 2.4% (WHO, 2020e). Strategies and best practices for improving
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the community response to COVID-19 worldwide should be adopted and implemented. This
health policy analysis will examine the evidence and recommend actions as the best way forward
to address society's health care needs during this COVID-19 pandemic and beyond.
Background and Scope of the Problem
COVID-19 is an infectious disease caused by the novel coronavirus transmitted from
person to person via airborne aerosol or droplets and contact with infected surfaces (WHO,
2020c). The droplets from the mouth and the nose during sneezing, coughing, and talking
contribute to the virus's fast spread, causing increased morbidity and mortality among the
infected individuals. These droplets have also accounted for the transmission of COVID-19
through the mucous membranes of the eyes (conjunctiva) and mouth (oral route) (Mick &
Murphy, 2020). There has been some misunderstandings and controversy regarding the
transmission of COVID-19 through the airborne route. Morawska & Cao (2020) explained that
after droplets are released, the droplets' liquid content starts to evaporate, making them smaller
than air current gravitational force. With their viral contents carried freely in the air, these
smaller droplets known as aerosols can travel meters and tens of meters to infect other
individuals through airborne transmission, especially in the absence of adequate ventilation
(Morawska & Cao, 2020).
According to WHO (2020d), the COVID-19 outbreak was declared a public health
emergency of international concern on January 30, 2020. Since the disease has spread
worldwide, it was declared a global pandemic on March 11, 2020. The WHO (2020e) reported
53,507,282 confirmed cases of COVID-19 as of November 15, 2020, with the Americas (North,
Central, and South Americas) having the highest number (22,960,102), followed by Europe
(14,792,945) and South-East Asia in the third place with 10,015,731 confirmed cases. A total of
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1,305,164 deaths were also reported simultaneously as of November 15, 2020. The highest
number of deaths (675,735) came from the Americas (WHO, 2020e).
The mortality rate of COVID-19 has been monitored and traced monthly, which provided
critical epidemiological data. Looking at the cumulative trend worldwide (see Figure 1), the
mortality rate peaked in April at 7.2% and has decreased to 2.4% as of November 15, 2020. The
WHO region’s confirmed cases, deaths, and death rate as of October 17, 2020, showed a surge in
the number of confirmed cases, although with lower deaths and death rates in all regions,
affecting population health (see Figure 2). Monitoring the death rate of COVID-19 provides
essential information about how severe the pandemic continues to be, and it is a crucial indicator
of continuous efforts to mitigate this pandemic. The WHO regions and individual country’s data
(see Figures 3, 4, 5, and 6) about the confirmed cases and the number of deaths were traced at the
end of every month. The data shows certain distinct regions and countries with very high
numbers, which likely reflects the trend in the widespread activity of the virus and the
effectiveness of prevention strategies. The data calls for continuous action to mitigate the spread,
morbidity, and mortality of COVID-19 globally.
The spread of COVID-19 from country to country reflects the interconnectedness of each
country around the globe. There are individual movements from one country to the other for
trade, leisure, and healthcare. This movement makes it difficult to contain the spread of
contagious diseases in a location, area, or country without completely sealing off the borders;
therefore, it provides the basis for the importance of a global effort to address global health
issues such as the COVID-19 pandemic. Rudnicka et al. (2020) stated that the global health
community needs to take action to slow the continual spread, morbidity, and mortality of
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COVID-19. Implementing global public health measures to detect, prevent, and respond to
health issues, including an infectious disease outbreak, is paramount to combat the problem.
There are inequalities in countries' capacity to prevent, detect, and respond to outbreaks,
which creates challenges in controlling the spread of infectious diseases from one country to the
other. In their analysis, Kandel et al. (2020) noted that only half of the analyzed countries have
strong operational readiness in place for health emergencies. They stated that strengthening the
global readiness for outbreak control, capacity building, and collaboration between countries is
needed (Kandel et al., 2020). Multiple approaches using financial, legislative, and executive
actions are needed to control the spread of COVID-19. These will involve the participation of all
segments of the society, both the public and the government.
Problem Identification and Understanding
According to the WHO, on December 31, 2019, pneumonia of unknown origin was
reported in Wuhan's city in the Hubei province, China. The virus was believed to have originated
from bats to anteater-like animals called pangolins before crossing over to humans (Rahhal, &
Dyer, 2020). The WHO branch in China closely monitored this virus. The spread of COVID-19
to other countries within one month prompted the WHO officials to develop a strategic
preparedness and response plan (SPRP) with a $675 million fund from the United States
covering the months of February through April (WHO, 2020d). The purpose of the SPRP was to
protect countries with weaker healthcare systems vulnerable to the virus outbreak. The SPRP
covers the areas of international coordination, readiness to research, and innovation aimed to
provide early care, limit transmission, minimize social and economic impacts, and communicate
essential information (WHO, 2020d). The national governments, multilateral organizations,
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private foundations, philanthropies, and other donors coordinated efforts to assists the WHO in
funding this initiative.
Some factors have contributed to COVID-19 spread from the origin in Wuhan, China.
Little was known about this new disease until its widespread impact around the globe. It was
believed that international travel for trade, leisure, and other businesses had contributed to the
rapid spread of COVID-19 as well as poor hand hygiene and close contact. Tracing how
COVID-19 has spread, the Cambridge University scientists identified three virus strains causing
COVID-19 across the globe. Two strains were traced to have spread to the United States of
America (USA) (Rahhal, & Dyer, 2020). They noted that the original strain of the virus from
Wuhan China spread to the West Coast in the USA and also affected Japan and Australia
(Rahhal, & Dyer, 2020). Different strains mutated from the original strain spread in China before
moving on to Europe and the East Coast in the USA to New York, and as well as to Canada
(Rahhal, & Dyer, 2020). The COVID-19 virus was believed to have been in New York
circulating unknown for weeks before being diagnosed due to the presence of asymptomatic
cases that is still a big challenge currently (Rahhal, & Dyer, 2020). Efforts to reduce the spread
of COVID-19 require measures to mitigate spread from asymptomatic carriers as individuals
move across each spread region.
The travel data from December 2019 and January 2020 shows that before China was
banned from entering the United States (US) on January 31, 759,493 people had entered from
China (Rahhal, & Dyer, 2020). The European countries were not banned at the same time. China
was banned from entering the United States, even when data shows some isolated cases in
Europe in late January. This inconsistent act allowed millions of people to enter the US from
European countries such as Italy, Spain, and Britain. The same issue happened to many countries
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worldwide. The inability to seal off the borders completely provided the channel for infected
symptomatic and asymptomatic individuals to move across different countries spreading
COVID-19. Experts stated that, although the virus mutates, the newer strains do not appear to be
more deadly than the original strain. The virus mutates very slowly, with only slight differences
between different strains (Rahhal, & Dyer, 2020). This slight difference is vital information that
affects the development of vaccines and treatment approaches worldwide to deal with the
COVID-19 pandemic.
Community spread of COVID-19 was reported as confirmed cases of COVID-19 in the
community continue with no history of recent travel or known source of exposure. Crowded
situations, close physical contact, enclosed space, and long duration of exposure are the factors
that may increase community spread (CDC, 2020c). The epidemiology of COVID-19 is
becoming more apparent as estimates of transmissibility, severity, and researchers are
continuously refining the population affected. COVID-19 is efficiently transmitted in the
community with an increased number of asymptomatic carriers (Mayo Clinic, 2020a). With this
knowledge of asymptomatic COVID-19 patients spreading the infection in the community
unknowingly, measures to mitigate the potential widespread COVID-19 need to be addressed.
Timely implementation of measures such as banning mass gatherings, temporary school
closures, the mandatory wearing of masks, appropriate disinfection and/or hygiene measures, and
isolation of ill persons reduced mortality in several US cities during the 1918-1919 influenza
pandemic (Cowling & Aiello, 2020). Vigilant adherence to these measures is even more vital in
our present small and easily assessable global world. Ensuring effective implementation of
mitigation measures continuously and timely in the community will reduce the community
spread of COVID-19.
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Covid-19 symptoms vary from one individual to another. Some patients can be
asymptomatic, while some may be pre-symptomatic and symptomatic. Symptoms could be mild
or severe and may lead to severe complications and possibly death.
Studies with large samples have estimated that 1.2-12.9% of COVID-19 patients are
asymptomatic. In comparison, smaller sample studies have the number at 87.9%, noting that the
asymptomatic patients remain a potential source of COVID-19 spread in the community (AlSadeq & Nasrallah, 2020). Being asymptomatic does not mean one cannot spread the virus, and
asymptomatic patients can have complications from having COVID-19. Studies have shown that
asymptomatic patients have shown some inflammatory lung abnormalities such as striped
shadows or ground-glass opacities on a CT scan, and a pulmonologist and critical care physician
at a New York hospital in Brooklyn (Huang, 2020) noted the same. Some of the most common
symptoms (see Table 1) include fever, tiredness, and dry cough, nasal congestion, body aches
and pains, headache, sore throat, conjunctivitis, diarrhea, loss of smell or taste, and skin rash or
discoloration of fingers or toes (CDC, 2020b; WHO, 2020b).
Cutaneous manifestations have also been noted mostly in children and young adults but
were also seen in older adults. Some of these lesions appear popular and reddish like chilblains,
become more purpuric, and flattens within a week (Landa et al., 2020). The location of COVID19 lesion presents in different locations such as the toes (COVID toes), soles, fingers, or heel. It
can be seen in both symptomatic and asymptomatic COVID-19 patients (Landa et al., 2020).
Kawasaki-like symptoms such as non-purulent conjunctivitis, polymorphic rash, mucosal
changes, and swollen extremities were also noted in children five to seven and a half years old,
although fewer of these classic symptoms were noted in a few older children (Viner and
Whittaker, 2020)
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New onset of confusion, flushed lips or face, and an inability to wake or stay awake have
also been reported, and symptoms may appear two to fourteen days after exposure to the virus
(CDC, 2020b). Some of the complications of COVID-19 (see Table 1) include pneumonia with
shortness of breath, heart problems, multiple organ failure, blood clots, and other bacterial and
viral superimposed infections. A study by Chen et al. (2020) identified that Acinetobacter
baumannii and Klebsiella pneumonia are among the pathogens identified in Covid-19 positive
patients' cultures. Another study by Xing et al. (2020) identified the most common COVID-19
coinfection caused by respiratory pathogens (see Figure 7) to be influenza virus A (60.00%).
Influenza virus B (53.30%), mycoplasma pneumonia (23.30%), and Legionella pneumophila
(20.00%).
Having comorbidities contributes to severe complications from COVID-19 as the
individual’s immune system and the effect of specific treatment may aid the infection's
progression. The study done by de Lucena et al. (2020) concluded that individuals with
cardiometabolic diseases such as hypertension and diabetes were at an increased risk of
complications from COVID-19 due to increased immune response dysregulation.
Some studies have raised the issue of Angiotensin-Converting Enzyme (ACE), and ACE
2 receptor overexpression as the COVID-19 virus enters the cell, aiding the rapid multiplication
of the virus in the infected individual's body cells (de Lucena et al., 2020). To understand further
the role of ACE2 in inactivating the ligands for the bradykinin receptors, Roche and Roche
(2020) explained that the COVID-19 virus enters host cells through the transmembrane protein
receptor (ACE2) in the lung tissue, decreasing its activities. Kinins are molecular protein
fragments that help lower blood pressure and allow fluid to leak out of the blood vessels. Experts
believed that the depletion of ACE2 activities by COVID-19 caused dysregulation in the
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inactivation of the desArg9 bradykinin (the ligands of B1R), worsening local vascular leakage in
the lung tissue leading to pulmonary infiltrate and difficulty breathing (Van de Veerdonk et al.,
2020).
Rapid multiplication of the COVID-19 virus also generates an excessive inflammatory
response with the release of pro-inflammatory cytokines, causing cytokines storm, which harms
and rapidly destroys healthy cells (de Lucena et al., 2020). Exploring and targeting this
bradykinin system may present a new and great therapeutic window as COVID-19 treatment
options continue to be researched.
High-Risk Populations
Although Covid-19 can affect anyone with mild to severe symptoms or no symptoms,
certain factors put some individuals at a higher risk of complications and possibly increased
mortality. Older people or individuals with existing chronic medical conditions, such as lung
disease, heart disease, diabetes, chronic kidney or liver disease, severe obesity, or those with
compromised immune systems, may be at higher risk of poor outcome and serious complications
from contracting Covid-19 (Mayo Clinic, 2020a). It is important to note that people without risk
factors also succumb to COVID-19, affecting all gender and age groups.
Different age groups respond to COVID-19 differently. Older adults and people with
comorbidities may have severe symptoms and more complications from COVID-19 than
younger and healthy adults may. Some children are mostly asymptomatic, but they could also be
affected sometimes with less severe symptoms, although in some cases, they can quickly
progress to respiratory distress syndrome (Dong et al., 2020). Children have also presented with
some symptoms resembling Kawasaki syndromes, as previously mentioned. However, a new
childhood inflammatory disorder referred to as multisystem inflammatory syndrome in children
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(MIS-C) was identified (Levin, 2020). This disorder is rare but occurs two to four weeks after
contracting COVID-19 in patients below 21 years of age, with a high proportion noted among
black, south Asian, and Hispanic patients (Levin, 2020). The MIS-C can be severe with
cardiovascular manifestation, and most have recovered with intensive care management with a
range of immunomodulatory agents (Levin, 2020). Knowledge of all these COVID-19
presentations and variations is essential for managing patients and minimizing spread and
complications.
There has been some research regarding COVID-19 virus transmission in utero,
especially knowing that in the past other viral infections such as rubella and Zika included
placental infection and transmission. A recent study showed a newborn baby reported positive
for COVID-19. The mother, who tested positive post-birth with a viral test known as reverse
transcription-polymerase chain reaction (RT-PCR) nasopharyngeal anal swabs, identified the E
and S gene of the COVID-19 virus (Vivanti et al., 2020). A study of the maternal placenta tissue
identified a small amount of key cell surface receptors and high ACE2. The ACE2 allows the
COVID-19 virus to enter the cells and replicate (Vivanti et al., 2020; Wang et al., 2020).
COVID-19 in neonates can cause cerebral vasculitis leading to neonatal viremia, fever,
pneumonia, and neurological symptoms including lethargy, vomiting, irritability, axial
hypertonia, and opisthotonos (Vivanti et al., 2020). Zeng et al. (2020) recommended that
screening pregnant women and implementing stricter infection control measures, quarantining
infected mothers, and closely monitoring neonates at risk of COVID-19 be implemented strictly.
Knowledge of these new developments will help develop effective preparedness in the care of
pregnant patients and their newborns to minimize complications.
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Racial and Ethnic Minority Population
Racial and ethnic groups have been noted to be disproportionately affected by the
COVID-19 pandemic. In the documentary, Pandemic: A Nation Divided presented by the WGN
news in Chicago, Illinois, the Latino race was noted to have an increased infection rate.
However, the black race was noted to have an increased number of deaths from COVID-19
disease, and the same data is seen in multiple states across the United States of America. This
signifies the disparity associated with the Covid-19 disease, where Latinos in some states were
most affected, and some other states have the blacks most affected. The impact of COVID-19
has divided the country in a very significant way depending on race and ethnicity. The black and
brown communities have been dealing with disparities in healthcare services provision, coupled
with a lack of access to healthy food, suitable housing, well-equipped hospitals, health centers,
and inequality in providing the needed healthcare services. These issues have long placed this
population to have multiple comorbidities that may affect an individual’s response to COVID-19
if contracted.
Underlying health conditions and lower access to care are the primary cause of poor
outcomes related to health care disparity. This disparity increases racial and ethnic minority
groups' vulnerability in public health emergencies such as outbreaks of COVID-19 virus
infections. Issues such as not having health insurance and the inability to pay for healthcare
services have contributed to poor health with multiple comorbidities among the black and
Hispanic communities. According to the CDC (2020c), individuals with no health insurance are
threefold in Hispanics and double in African Americans than Caucasians. All these factors have
contributed to increased morbidity and mortality among these vulnerable populations when it
comes to Covid-19 infections. A higher risk of severe complications from COVID-19 has also
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been noted among Native Americans because they are prone to having diabetes, heart disease,
and other conditions (The Harvard Gazette, 2020). This population seems not to have much
publicity regarding COVID-19 despite their worsening situation. As of April 30, the thirdhighest per capita rate of COVID-19 in the country is in the Navajo nation, after New Jersey and
New York (The Harvard Gazette, 2020).
Employment environments and circumstances could also contribute to the racial and
ethnic minority’s risk of contracting Covid-19 and being severely sick. Work environments, type
of work, and work policies have been unfavorable for this vulnerable population. According to
the CDC (2020c), almost 25% of Hispanic or black workers are employed in service industry
jobs that eliminate the possibility of working from home compared to 16% of non-Hispanic
whites. Hispanic workers account for 53% of agricultural workers (CDC, 2020c), which often
lack policies and benefits such as paid sick leave. These factors contribute to employees working
even when sick; therefore, this crisis may increase the risk of spreading the COVID-19 virus.
There are lower paid sick leave rates in Hispanic workers than white non-Hispanic workers
(CDC, 2020c).
Communal Resident Situations
Living conditions also contribute to the underlying health conditions that will affect how
people respond to and prevent the spread of COVID-19. The crowded, living in communal
residential situations, has contributed to the rapid spread of the Covid-19 virus among the
affected communities. The majority live in a densely populated area such as in jail, assisted
living, group homes, shelter, college dormitory, multilevel residences, or multi-generational
living conditions. These populations are predisposed to an increased risk of COVID-19 spread
due to their inability to practice social distancing. Long-term care facilities residents experienced
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increased mortality rates from COVID-19 due to multiple factors, including living situations and
multiple comorbidities. Testing and contact tracing policies, as well as other COVID-19
mitigation policies, should hold strict adherence.
Assisted living facilities, group homes, and shelters were highly affected by COVID-19
due to their congregate living situations and habitats having multiple comorbidities, especially
among their elderly population. Given their congregate living situation and the elderly
population they serve, there is a high risk of increased spread of COVID-19 with increased
morbidity and mortality. The CDC (2020a) has recommended source control measures to limit
the spread and severity of COVID-19 in assisted living facilities. Such measures include the
prompt identification of the point of contact, which has resulted in visitors' restrictions and
screening of residents and staff in assisted living. With the increasing number of asymptomatic
cases of COVID-19, the living situations that limit social distancing, and possible quarantining,
rapid action is required to identify, isolate, and test residents and others that might have been
exposed promptly to prevent further the spread of COVID-19 (CDC, 2020a)
Congregational living in the jails, prisons, and detention areas increases the risk for
COVID-19 infection. The living set-up and overcrowded conditions make it very difficult and
impossible for the inmates to practice social distancing or quarantine. Incarcerated people are at
a significant risk of increased morbidity and mortality from the Covid-19 infection. This required
strategies to reduce the jail population, such as releasing those who are not a threat to public
safety or are elderly or infirmed (Equal Justice Initiative, 2020). The infection rate of Covid-19
in jails and prisons is about 2.5 times higher than in the general population nationwide (Equal
Justice Initiative, 2020).
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Congregational living in jails, prisons, and detention areas are overrepresented by the
racial and ethnic minority groups (CDC, 2020c), increasing their risk for COVID-19 infection in
these facilities. Multilevel residences or multi-generational living conditions are common among
the ethnic and racial minority group and contributes to the inability to protect the elderly and
provide proper isolation of the sick ones. As noted by the CDC (2020d), social distancing, which
is to reduce physical interaction between people and keeping six feet apart, remains an essential
part of the prevention of COVID-19 spread. Unfortunately, the multi-generational living
condition makes it impossible for this to happen. The presence of the elderly in such living
conditions with co-morbidities worsens the situation.
With school reopening and students going back to college dormitories and crowded
classrooms, maintaining social distancing remains a significant challenge. Preventive measures
such as wearing a mask, quarantining if exposed, contact tracing, isolating if sick, hand washing,
and frequent cleaning of surfaces is recommended (CDC, 2020d).
Healthcare Workers and First Responders
Healthcare personnel (HCP), including first responders, are at increased exposure to the
COVID-19 virus and are dependent upon personal protective equipment (PPE). A total of 90,626
HCP have been reported to have confirmed Covid-19 in the United States as of July 2, 2020. The
United States HCP continues to experience widespread cases of Covid-19 (CDC, 2020c). Cases
among HCP have increased, and based on available data as of August 24, 2020, 142,935 cases of
COVID-19 and 660 deaths from COVID-19 have been reported among HCP (CDC, 2020c). The
shortage of PPE’s and limited access has posed a great challenge to this population and further
increased their risk of contracting COVID-19. According to Emanuel et al. (2020), front-line
health workers and others who provide care and those who keep critical infrastructures operating
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should be given priorities to PPE, therapeutics, and vaccines access because they are essential
pandemic response.
Guidelines
Several states, national and international guidelines, and policies related to Covid-19
have centered on ways to prevent and minimize the spread of the Covid-19 virus. Prevention
strategies are focused more on preventing the spread of the disease, while treatment alternatives
for sick individuals are still under development. Unlike some other countries that follow their
national guidelines, different states determine the scope of their prevention guidelines in the
United States.
The following are recommendations from the CDC (2020d) and the WHO (2020a);
individuals should be aware of how the Covid-19 virus spreads and take the necessary
precautions. Symptomatic and asymptomatic COVID-19 positive patients should monitor their
temperature, be alert for worsening symptoms, and know when and how to seek medical care.
Individuals need to maintain a social distance of six feet, or two meters between each other,
especially those with a high risk of severe disease. Staying home as much as possible and
avoiding close contact (within about 6 feet, or 2 meters) with sick people or have symptoms of
Covid-19 is recommended. It is essential to know that some people may not have symptoms or
know that they have COVID-19 and can spread it to others. Large events and gatherings should
be avoided, and hands should be washed often with soap and water for at least 20 seconds or at
least 60% alcohol-based hand sanitizer if soap and water are not readily available. People need to
avoid touching the face with unwashed hands, cover nose and mouth with a facemask in public
spaces, and avoid close contact with one another, such as in grocery stores, especially in
continuous community areas. Cloth covering should not be substituted for social distancing.
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They do not recommend masks for children younger than two years of age, unconscious people,
those with difficulty breathing, or anyone who cannot remove the mask.
Additional recommendations include instructions to avoid touching eyes, nose, and
mouth, cover nose and mouth when sneezing and coughing with an elbow or tissue paper, and
safely discard used tissue and wash hands immediately. Do not share glasses, dishes, towels,
bedding, and other household items when sick. Daily disinfect and clean high-touch surfaces
such as light switches, doorknobs, counters, and electronics used frequently with soap and water
and EPA approved cleaning agents for COVID-19. Individuals with COVID-19 symptoms
should stay home from work, school, and public areas unless they go for medical care and avoid
public transportation as much as possible (CDC, 2020b).
State and Local Government Recommendation
Local and state governments issued recommendations to reduce the spread of the Covid19 while moving in the direction of the safe reopening of the economy. The Covid-19 pandemic
has affected every part of the world in many different ways, and this will require some strategies,
innovations, and coordinated resources to return to normal living conditions. In the United States
of America, different cities and states have initiated their specific re-opening strategies with
different stages tailored to the severity of COVID-19 in the area and progress made toward
reducing the spread.
Impact and Significance
Starting from the early days of the COVID-19 pandemic, there have been changes in the
life pattern of individuals, families, communities, and entire countries. Apart from the health
effects of contracting the COVID-19 virus and being sick, individuals, communities, and the
global world have seen changes in the way they live and function. Since this is a new virus,
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ongoing changes in handling the COVID-19 pandemic have emerged, and a lot is still being
learned about the virus. When this pandemic started, the most important goal is to stop or contain
the spread, and several strategies were immediately put in place. These strategies include; social
distancing, hand washing, and use of PPE to take care of sick people, then staying at home,
wearing masks in public, cleaning, and disinfecting surfaces. As the COVID-19 virus infection
continues to spread, closing non-essential places and businesses, reducing the number of
gathering, canceling large events, closing schools, and restrictions on international travel, were
added as more measures reduce the spread. The spread of the COVID-19 virus infection and the
strategies being implemented to minimize its spread have affected both the local, national, and
international economies in many ways.
Local
Covid-19 has affected the local communities across every state in the United States. The
devastating effects have divided the community leaders as well as the church leaders in most
communities. Some individuals and communities are affected and require resources more than
others require. There is poor access to healthcare services, as most clinics are closed with no
information on how patients can receive care. Personal protective equipment such as masks and
gloves are very scarce, especially to the community and long-term care facilities leading to an
increased COVID-19 virus spread, morbidity, and mortality. The CDC has implemented
mitigation strategies for communities. However, some local communities, especially the racial
and ethnic communities, are still struggling with health disparities affecting the efforts to stop the
spread. While the communities work to reduce COVID-19 spread, economic, secondary health
issues, and social consequences of diseases are also being addressed. Efforts should be
community-centered to address the specific needs of different communities.
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Individually, the COVID-19 pandemic has caused unemployment and income loss,
increased frustration and suffering, and increased mental health sickness, especially depression
and anxiety. Congruently, there has been an increased incidence of violence and addictions to
non-recreational drugs and alcohol. Some other illnesses, such as obesity and cardiovascular
diseases, have also been rising from increased inactivity. Families are faced with fear and anxiety
of separation from loved ones and mourning their loved ones who died from COVID-19 related
complications. Lack of PPE remains a great challenge for healthcare professionals and the public
as the COVID-19 pandemic continues.
The communities have been greatly affected as schools, local shops, healthcare centers,
and private clinics were closed during the stay at home orders. The effects of these closures
remain economically devastating in addition to an increase in the effects of health disparities,
violence, mental health problems, and addiction. The low socioeconomic and ethnic minority
communities are challenged with poor access to healthcare services, inability to maintain social
distances due to poor living conditions, and lack of healthy and non-healthy food supply. Limited
COVID-19 testing, contact tracing, increased co-morbidities, and the continual spread of
COVID-19 has greatly increased the morbidity and mortality rate in these communities.
State
Statewide, healthcare facilities' operations were disrupted as elective surgeries were being
canceled, affecting some health maintenance procedures such as colonoscopy and others that
may indirectly affect health. Most hospitals, especially the safety-net hospitals that are already in
financial crisis, faced greater financial challenges from loss of outpatient and elective surgery
services that influenced their ability to provide resources and pay salaries. Some outpatient
clinics closed unexpectedly, with patients having difficulty contacting their provider, affecting
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their ability to receive medical advice or refill their medications. A survey of health care
providers, mostly in private practices, revealed significant adverse effects ranging from a decline
in visits and clinical activities to a reduction in the health care workforce, with a consequent
reduction in revenues associated with economic distress (Song et al., 2020).
Different states are impacted differently depending on the rate of COVID-19 spread and
the number of individuals affected. Some states with a limited number of infections did not take
aggressive measures. In contrast, some other states such as New York, Illinois, Michigan, and
New Jersey, with increased COVID-19, cases, and deaths have implemented severe measures.
The measures range from school closing to shelter in place, cancellation of events, closing nonessential business, limiting bars and restaurants to curbside pick and deliveries, and interstate
flight limitations. With businesses, casinos, and tribal enterprises closed, Native Americans were
left with no or limited resources to run their health clinics and provide for foods. All these
measures are to minimize the spread of COVID-19 but, at the same time, have affected the
economy greatly. Most states reported spending a huge amount of money on PPEs, ventilators,
hiring extra healthcare workers, and building more hospitals and healthcare facilities to care for
the surge of COVID-19 patients. However, the shortage and effective distribution of PPEs
remains a continuous challenge. Unemployment benefits have added to the financial difficulties
as the state shoulders part of the expenditure. These expenditures have put a stretch on the state
budget despite some relief from the federal government.
National
Nationally, the impact has gone from healthcare system limitation on services to the
financial effects on infrastructures and business, immigration services hold, and several federal
government executive orders. The agricultural sector has seen a decline in the workforce and
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food processing industries affecting certain foods' availability. The CDC has collaborated with
the state and local public health departments to issue and update guidelines to follow during this
pandemic. The financial burden continues to increase as the pandemic progresses. Providing the
stimulus package to help small businesses and provide financial assistance to individuals was
helpful but still not enough as the situation worsens. The federal government is faced with a
great economic challenge with a worsening infection spread.
Global
COVID-19 has several national and international impacts, although its severity varies
depending on the number of individuals affected and the strategic response implemented. Most
countries' economy was crippled as businesses and schools were closed, and the ban on
international travel that affected international trades and businesses led to economic difficulties.
Efforts to decrease the spread of COVID-19 have led to travel restrictions, border shutdowns,
and quarantining, which increases the risk of recession and economic crisis. Nicola et al. (2020)
has summarized the effect of COVID-19 on the world economy into primary, secondary, and
tertiary sectors. Primary sectors involve industries that are concerned with the extraction of raw
material. Secondary sectors deal with the production of finished products. Tertiary sectors
include industries that provide services.
Quarantining, social distancing, and travel restrictions have caused a reduced workforce
across all economic sectors leading to job loss and major economic difficulties (Nicola et al.,
2020). There are shut down in businesses, leading to a decrease in commodities and
manufactured products, with a significant increase in medical supplies. Schoolchildren's closure
comes with much impact and challenges as schoolchildren were diverted to an online learning
platform. Many people struggle to navigate the trending e-learning system. One of the strongest
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predictors of the health and the wealth of a country's future workers is education. There has not
been a clear quantification of the impact of long-term school closure on educational outcomes,
young people's health, future earnings, and future national productivity (Viner et al., 2020).
Nicola et al. (2020) stated that the road to the recovery of the economy is predicted to belong
with many years of economic inactivity. The recovery from the economic, political, and
manufacturing sectors will require well-formulated strategies for a successful outcome to address
international travel and trade, immigration, migration, and food supply problems. A big picture
illustration (see Figure 8) provides a visual overview of the general concept of COVID-19 best
practices and the way forward.
Analytical Framework
In this policy analysis project, a theoretical framework is valuable as it increases the
effectiveness of the process and provides guidance for systematic policy analysis (CDC, 2015).
The CDC policy analytic framework and Kingdon’s multiple-streams theory will guide this
analysis project and work toward bringing about the best practices for COVID-19. The
framework that will guide the structure of this project is the CDC policy analytical framework.
The critical step of the CDC’s policy analytical framework includes:
•

To identify the policy issue or problem

•

Identify solutions for the problem or issues, including identifying and describing the
policy options, assessing policy options, and prioritizing policy options.

•

Develop a strategy for the adoption of the policy solution (CDC, 2015).

The issue identified is not only the infection with COVID-19 but also the impact it has on the
global world. In the second step, the guidelines and recommendations to reduce the spread of
COVID-19 were identified. As the infection progresses, specific changes were made to ensure
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that the best practice is being implemented for a successful outcome. Moreover, in the final step,
some options and alternatives to the current practice are being explored. Recommendations will
be disseminated to the appropriate stakeholders (public, healthcare professionals, consumers, and
legislators).
Theory
The theory that guides this project is Kingdon’s multiple-streams theory, which is
concerned with the agenda-setting incorporating precise relationships among variables (Walt et
al., 2008). In this theory, there is a belief that the public policy process has a random character,
with problems, policy, and politics flowing along in independent streams (Walt et al., 2008). The
idea is that the streams merging will create a window of opportunity for actions such as policy
discussion and adoption to take place. The three streams of the theory remain the three angles
that interact as they merge to stimulate beneficial actions, especially in the issue of healthcare
policy. In the problem stream, the broad issue or problem facing the global world identified is the
COVID-19 pandemic requiring public and private attention. The policy stream incorporates
ideas, guidelines, and recommendations on how to deal with the problem of COVID-19. The
politics stream involves the political transitions guided by the national mood and social pressure
regarding the need to change to improve the problem (Walt et al., 2008). According to Gregg et
al. (2018), policy entrepreneurship raises awareness of issues and proactively creating policy
alternatives while providing a roadmap for future policy leaders.
Evidence Search Strategy, Results, and Evaluation
An electronic search of the following databases CINAHL, PubMed, EBSCOhost, and
Google Scholar, was used to conduct a literature search. Filters were applied to the selected
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studies written in English. Some evidence was also obtained directly from government websites
and grey literature from a credible news source.
Owing to this project topic's nature and timing (COVID-19), most of the articles
addressed coronavirus and other viral infections but not the actual virus (SARs CoV-2) that
caused COVID-19 were eliminated. The articles were screened with filters, and some exclusions
were applied, and 30 articles (see Appendix A) were used for the evidence review. Keywords
used: COVID-19 pandemic, Coronavirus protection, Preventing COVID-19 spread; COVID-19
and economic impact, COVID-19 safe reopening, and vaccine trials. John Hopkin’s evidence
level and quality grade (see Table 2) from Hopkins Medicine (n. d) was used to evaluate some of
the articles as level I, II, III, and quality grade A, B, C, while some of the articles were from
credible and reputable government websites. Some of the evidence was also obtained from
professional organizations' websites and grey literature such as interviews, news, and panels.
Themes from Evidence Review and Recommendation
This section will identify the themes from the currently available evidence and provide
recommendations for actions. The themes identified in this evidence review are; prevention
strategies, supportive treatment measures, treatment and vaccine trials, testing, contact tracing,
managing stress, mental health and healthcare access, the safe reopening of the economy, and
education and creating awareness.
Prevention Strategies
Preventing the spread of COVID-19 remains the best approach at this time for effective
control, as there is no current cure or vaccine available. To reduce the spread of COVID-19,
preventive strategies such as hand washing, avoiding close contact, social distancing, covering
cough and sneezes, wearing masks, cleaning and disinfecting frequently touched surfaces, and
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wearing appropriate PPE’s should be followed (Ashour et al., 2020; CDC, 2020d; Illinois
Department of Public Health (IDPH), 2020; Johns Hopkins Medicine, 2020; Srivastava &
Saxena, 2020; WHO, 2020b). Srivastava and Saxena (2020) added that maintaining good
immunity and a healthy diet with vitamins, especially C and E and exercises, can help fight
infections such as COVID-19. Everyone has a part to play in slowing the spread of COVID-19,
as individual behavior remains an essential factor in this regard. Compliance with hand hygiene
guidelines, social distancing, cleaning, disinfecting surfaces, and PPE use is vital (Anderson et
al., 2020).
Hand Hygiene
Handwashing remains the single most effective measure to reduce the spread of
infections (Canadian Centre for Occupational Health and Safety, 2020) even before the
coronavirus infection started. However, unfortunately, it remains a problem for compliance
among the public and healthcare professionals. Some specific guidelines on effective
handwashing include washing hands often with soap and water for at least 20 seconds. Sixty
percent of alcohol-based hand sanitizer may be used if soap and water are not readily available
(CDC, 2020d; Srivastava, & Saxena, 2020; WHO, 2020d).
Recommendation. Mandate the installation of water and soap or hand sanitizers in
public places. This is very important as an effort to prevent COVID-19 spread continues. Easy
access to the hand sanitation process will help to promote compliance. Public places such as train
stations, grocery stores, bars, restaurants, and churches, need to follow an established standard
provision for hand hygiene stations to operate and penalties should be given to those not meeting
the established standard. The health department and the occupational safety and health
administration (OSHA) regulations should mandate this recommendation and follow up with a
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periodic inspection to ensure compliance. Every public place needs to have a station for hand
hygiene. Establishing and enforcing a standard will improve compliance with the single most
effective measure to reduce the spread of infections.
Another recommendation is to educate and reinforce hand washing for all. Provide
continuous education and reminder for the public, from children to adults, using teaching tools,
videos, billboards, signposts, and media with a clear and concise message. Professional
organizations should set an agenda to address handwashing for all ages, as was done to provide
helmets for safety programs or car seats for safe transport program.
Social Distancing
Certain measures are recommended to reduce the spread of the COVID-19 virus from
one individual to another, including maintaining six feet of social distancing. Self-isolation and
quarantine (see Table 3) are also recommended (CDC, 2020d; Srivastava, & Saxena, 2020).
Keeping away from large group gatherings will help in social distancing. However, there are
situations where maintaining social distancing may seem impossible such as in grocery stores,
multi-generational living situations, and shelters. Concerted efforts to maintain safety are
encouraged, including hand washing, cleaning and disinfecting surfaces, and wearing a mask.
Ensuring a national standard in addressing these preventive measures will be beneficial.
Recommendations. The first is to establish a standardized national framework for
infection prevention strategies for current and future health emergencies. The second is to
replace the state-by-state guidelines on social gathering and other preventive measures with a
national standard for the present and future infectious diseases outbreaks. A national standard to
guide the preventive strategies will help to minimize the interstate spread of COVID-19 and help
to minimize its impact. Establishing uniform national guidelines is in line with global health
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preparedness that will curb the current pandemic and future challenges. Three DACH countries
(Germany, Switzerland, and Australia) that share the same borders in central Europe were very
successful compared to other European countries in preventing the negative impact of COVID19 even when faced with the same epidemiology situation (Desson et al., 2020). They
implemented a standardized approach to infection preventive strategies to reduce the spread and
impact of COVID-19 effectively. The declaration of the national state of emergency in
Switzerland and Australia was responded to by shifting the decision-making powers of
independent states to the central government (Desson et al., 2020).
East Asian regions such as Taiwan, Japan, and Thailand, and some Central and Eastern
European countries such as Czech Republic, Poland, and Ukraine, implemented the national
standard of public mask-wearing, contributing to the slowing down of the spread of COVID-19
(Chan, 2020). The standardized approach has proven to be effective. It should be implemented
globally by establishing and adopting a framework that will guide and direct uniform national
approaches to preventive measures by all the states or regions of a nation. This standard
framework will allow measures such as mask-wearing, event restrictions, border closures, shelter
in place, schools, restaurants, shops, bar closures, and reopening to be implemented uniformly
and timely throughout a nation.
Cleaning and Disinfecting Surfaces
The CDC has recommended the use of COVID-19 environmental protection agency
(EPA) approved cleaning agents in addition to routine cleaning with soap and water. EPAapproved disinfectants against the COVID-19 virus are on the N list. They can be identified by
the EPA registration number on the cleaning agent (EPA, n. d.). Use the tool called List N:
Disinfectant for COVID-19, which is found on the EPA website (epa.gov) to identify if the
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cleaning agent is EPA approved for COVID-19. To use this tool, the first two numbers of the
first two parts of the registration number on the disinfectant label is entered, and the show result
button is selected to see if the disinfectant is among the list (EPA, n. d.). These approved
products are not for use on the human body or human consumptions but are for use on surfaces
while ensuring that the directions on the labels of the products are strictly followed. Alternate
disinfectants such as 70% alcohol or 1/3 cup of 5.25%–8.25% bleach added to one gallon of
water can be used in the absence of EPA-approved disinfectants (CDC, 2020d), but maintaining
safety in use and storing of these cleaning products is recommended.
Recommendation. Establish standard policies for cleaning and sanitizing public spaces,
including schools and businesses. These standard policies will guide different public places to
maintain safety by frequently cleaning areas as recommended using the right cleaning agent. In
collaboration with OSHA regulations, health departments should mandate the implementation of
this recommendation and conduct a periodic inspection to ensure compliance with a penalty for
defaulters.
Personal Protective Equipment (PPE)
Protection from getting in contact with the SARS-Cov-2 that causes COVID-19 entails
using barrier methods to avoid coming in contact with persons who have contracted the virus or
are suspected of being infected with the virus. The use of isolation gowns, masks, eye cover, and
face shields as PPEs have been recommended for healthcare workers, first responders, and other
individuals who are taking care of COVID-19 patients or persons under investigation (PUI) for
COVID-19 infection (Johns Hopkins Medicine, 2020; WHO, 2020a). As recent developments
have determined, some individuals tested positive for the COVID-19 virus but are asymptomatic;
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therefore, the use of a mask or some kind of face coverings have been recommended (CDC,
2020d).
In the United States, some states do not mandate masks in public, yet other states have
mandated that masks be worn publicly. The risk of transmission of COVID-19 was reduced with
universal masking due to the number of asymptomatic individuals increases (IDPH, 2020). Some
exceptions to general mask-wearing include children under two, individuals that are having
difficulty breathing, or people who are unconscious, incapacitated, and unable to remove the
mask (CDC, 2020d). The public masking recommendation is still not followed, as there is no
standardized national or global policy on wearing specific masks that can offer better protection
for all. Some different masks (see Table 4) include a dust mask, cloth mask, surgical mask, an
N95 mask, and other respirator masks; although Osborn (2020) noted that cloth masks were not
regarded as PPEs.
Recommendations. The first recommendation is to increase the production and
distribution of N95 masks, especially to high-risk populations. Second, fund and repurpose small
businesses to produce the needed PPE’s. Third, provide incentives to drive more businesses to
engage in PPE production. Fourth, establish a framework to ensure that PPE’s are equitably
distributed. The fifth is to make the use of the N95 mask mandatory for all with increased
availability and reduced cost. The lack of PPE has jeopardized the community's health as
provision and distribution of PPE to the community, group homes, shelter, safety-net hospitals,
and nursing homes have faced a vast supply and demand imbalance. Government and private
interventions to ensure PPE's continuous availability, especially to these high-risk populations,
are recommended. Medical resources should be carefully reexamined to identify potential
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shortages in the COVID-19 pandemic, and efforts to mitigate shortage should be timely
instituted.
There is convincing evidence that practices such as wearing a mask and other preventive
practices have helped slow the spread of COVID-19 in countries worldwide that have mandated
national mask-wearing from the pandemic's early stage. This effective strategy comes with its
challenges of availability and access as demand increases. The challenge of limited availability
of masks was quickly mitigated by countries like China, who supported small businesses,
boosted their local productions of masks and other PPE, and implemented rationing methods for
effective distribution (Chan, 2020). It is essential to understand that there is more to the adequate
supply of masks and other needed PPE to the public than just considering the stock. Chan (2020)
stated that for mask supply to be sufficient, it has to enhance local manufacturing capacity, set up
distribution networks, timely replenish stocks, and ensure equity and affordability of access.
Some East Asia region implemented grass-root initiated mask making and used their
digital infrastructures to ration mask distribution, ensuring equity and affordability of access
while supporting local businesses to boost production (Chan, 2020). An example is Taiwan using
its national insurance health record database to develop a rationing system for a successful mask
distribution (Lee, 2020). Here in the United States, the Medicare system could reach high-risk
populations and provide a covered mask and PPE distribution services. Some other parts of
Central and Eastern Europe also initiated grass-root mask making with financial assistance and
incentive for businesses that repurposed their businesses' line to boost mask production (Chan,
2020). These strategies have proven to be successful in other countries and should be adopted for
the present and in the event of other future emergencies. Apart from funding and giving
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incentives, collaborating with private and other government organizations, especially within the
communities, to establish small PPE production businesses will boost supply.
With the recent developments in airborne transmission of COVID-19, a more
comprehensive approach is needed to protect against the spread of COVID-19. Such approaches
will entail adequate protection from airborne COVID-19 RNA particles using an N95 mask. A
study by Mick & Murphy (2020) recognized airborne transmission during aerosolized
procedures but added that pursed-lip breathing, natural breathing, and cough could also produce
aerosols from the high viral loads in the upper aerodigestive tract. Since both symptomatic and
asymptomatic COVID-19 positive individuals carry viral loads of COVID-19 virus, adequate
protection will be achieved if the N95 mask is mandated and made available to all individuals
likely to be exposed to positive patients. A surgical mask may offer some protection level, but
N95 masks have 95% filtering of the virus and offer the most protection (Osborn, 2020). To keep
the population protected, using the N95 mask is essential. However, this comes with its
challenge of availability and affordability, and as such, the other recommendations to increase
availability and affordability need to be implemented.
An air sampling study performed in several hospitals using polymerase chain reaction
testing found several positive samples for SARS-CoV-2 genome (RNA) in the air of hospital
rooms of infected patients providing more clarity on airborne transmission (Morawska et al.,
(2020). A systematic review conducted by Bahl et al. (2020) showed that the COVID-19 virus
can remain viable for three hours after aerosolization in a COVID-19 infected individual. Based
on the weight of combined evidence, airborne precautions are also required with droplet
precautions (see Table 5) to maintain the healthcare workers' occupational health and safety and
others taking care of the patients with COVID-19.
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Another recommendation is to implement engineering controls in public buildings to
protect the public. Following the outcome of their air sampling study, Morawska et al. (2020)
recommended that engineering controls be implemented in public buildings such as schools,
churches, healthcare facilities, libraries, restaurants, shops, offices, and public transports. This is
important based on the current airborne transmission evidence, and it should be combined with
other preventive practices to help reduce the spread of COVID-19. The capital layout for this
type of engineering control project may be high, but allocating funds just like in the funding for
research and development of products and providing tax incentives similar to solar energy writeoffs that the public will help to implement.
Supportive Treatment Measures
Currently, supportive care measures (see Table 6), are being used to manage patients,
while therapeutic trials for COVID-19 medications and other treatments are still in progress. The
number of people affected by COVID-19 continues to increase globally. However, more than
80% have mild symptoms that can be self-managed at home, 20% lead to severe respiratory
compromise, and other complications requiring hospitalization (Bajwah et al., 2020). Providing
expert, symptomatic treatment for frail patients with multiple comorbidities to prevent avoidable
suffering remains a moral obligation in healthcare. Some of the symptoms (i.e. dry cough) are
triggered by the neuro-modulatory changes that heighten the cough reflex sensitivity. This is
often acute and self-limiting but intense and requires some supportive management (Bajwah et
al., 2020).
Many COVID-19 patients suffer from inflammatory and clotting problems that have been
linked to an immune-thrombosis reaction. This immune-thrombosis reaction is due to the
upregulation of pro-inflammatory cytokines with marked elevation of D-dimmers triggered by
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the intense stimulation of intrinsic fibrinolysis in the lungs (Thachil, 2020). Antithrombotic
therapy for the prevention of venous thromboembolic events is recommended. Heparin is an
antithrombotic medication used for its thrombin blocking action and is also used to reduce
inflammation (Fogarty et al., 2020; Lodigiani et al., 2020; Thachil, 2020).
Some experts treat bacterial co-infections such as pneumonia in COVID-19 patients with
antibiotics. In their systematic review, Lai et al. (2020) stated a possible bacterial co-infection
among COVID-19 patients. In a telephone interview, Dr. Richard Prudencio (Internist at Kaiser
Permanente, California, June 2020) stated that the facility utilized macrolide antibiotics such as
azithromycin as an adjunctive therapy to treat most COVID-19 patients that presented with
pneumonia, which was shown to be helpful. Experts believe that macrolides such as
azithromycin and clarithromycin have immunomodulatory and anti-inflammatory effects and
downregulate pro-inflammatory cytokines (Rizk et al., 2020).
Corticosteroids, as a non-specific immune modulator with potent anti-inflammatory and
antifibrotic properties, have drawn more attention in the supportive treatment of COVID-19
patients, particularly in severe cases. A low dose of corticosteroids is believed to play a role in
suppressing lung inflammation because it downregulates pro-inflammatory cytokine
transcription and improves the dysregulated immune response caused by sepsis, which a possible
complication of COVID-19 (Rizk et al., 2020). This downregulation of cytokines prevents
extended cytokine response and helps to resolve the systemic and pulmonary inflammation in
pneumonia (Rizk et al., 2020). With individualized therapy, steroids such as methylprednisolone
(or equivalent) and dexamethasone have contributed to reduced COVID-19 patients' mortality
but should be used for a short duration (Zhang et al., 2020).
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Some other supportive treatment for patients has been provided for hypoxia and anxiety
seen in a patient with COVID-19. Shortness of breath associated with COVID-19 may lead to
severe hypoxia as patients' breathing becomes labored. Depending on the oxygen saturation, the
patient may be given oxygen through the nasal cannula. However, in more challenging
situations, CPAP/BIPAP or mechanical ventilation may provide oxygen and support ventilation.
The difficulty in breathing and the feeling of breathlessness and fear and isolation from
significant others may cause anxiety, mild, moderate, or severe. Relaxation technique and
breathing exercise can be used for mild anxiety, while moderate to severe anxiety may need to be
managed with lorazepam or midazolam medications with good effect (Bajwah et al., 2020). The
critically ill patient from COVID-19 and those with complications will require more intense
treatments in the intensive care unit with ventilator support and other medications that can
sustain their hemodynamic functions.
Treatment and Vaccine Trials
The identification of medical treatment and the development of therapeutic agents that
can help to cure COVID-19 is a critical approach needed to assist those that contract the disease
to recover medically. Certain medications have been on trial to treat COVID-19 patients with
updates made on the current approach. The FDA issued an update on June 15 to revoke the
emergency use authorization (EUA) to use chloroquine and hydroxychloroquine to treat COVID19 patients (National Institutes of Health, 2020). Remdesivir is an antiviral medication that has
been on trial use through the FDA EUA for severe cases of hospitalized COVID-19 patients. In a
double-blind, randomized, placebo-controlled trial, Beigel et al. (2020) concluded that patients
who received remdesivir had a shorter recovery time and were more likely to have earlier
improvement than the placebo group. Based on the study data, Beigel et al. (2020) suggested that
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remdesivir treatment may have prevented the progression to more severe respiratory disease and
shortened the duration of oxygen and mechanical ventilation use in hospitalized COVID-19
patients. This study's outcome was in line with an earlier randomized trial of remdesivir by
Wang et al. (2020) in China that showed a shorter improvement time for hospitalized COVID-19
patients who received remdesivir in a smaller sample size (Beigel et al., 2020). According to the
news report on October 22, 2020, the U. S. FDA gave full approval to the use of Gilead’s
remdesivir as the only FDA-approved medication to treat hospitalized COVID-19 patients (Mail
Online, 2020). The positive outcome of remdesivir use will contribute to improved outcomes and
reduced use of health care resources that are already scarce during this pandemic.
The immune-based therapy trials using the convalescent plasma from COVID-19 patients
or SARS-CoV-2 immune globulins and the interleukin-6 inhibitors and interleukin-1 inhibitors
for the treatment of COVID-19 patients is still under trial (National Institutes of Health, 2020).
The current study had shown some benefit when COVID-19 convalescent plasma was used to
treat individuals with severe or life-threatening symptoms of COVID-19. Patients at risk for or
those with severe COVID-19 symptoms who received COVID-19 convalescent plasma within
three days of diagnosis have a better chance of surviving than those who did not (Mayo Clinic,
2020b). A patient that had COVID-19 must meet specific criteria to be able to donate plasma.
The criteria include no symptoms for 14 days, recovered with a negative COVID-19 test, and a
high antibody level in their plasma (Mayo Clinic, 2020b). Screening for other infections and
compatibility with the recipient blood group is done before plasma use. There are still some
unknowns in the use of convalescent plasma, such as the duration of the immunity and the
frequency or the number of times such treatment will be done as further research continuous.
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Vaccines play an important role in preventing infectious disease spread and, as such, save
millions of lives globally (American Nurses Association, 2020). The development of vaccines
for COVID-19 is significant for its eradication. Several vaccine developments are in progress by
different pharmaceutical research and development (R&D) units and researchers. There are
different types of immunity (see Figure 9), according to the CDC (2020d), immunity against
infections can be from vaccines or other sources. Approaches such as the use of vaccines made
from live attenuated virus, inactivated virus, replicating and non-replicating viral vectors,
recombinant protein sub-unit or virus-like particles, and researchers across the globe explore
nucleic acid (DNA and mRNA) as they try to develop COVID-19 vaccines (Srivastava & Saxena
(2020). Ahmed et al. (2020) stated an imminent need to understand this new COVID-19 virus
well as vaccine development progresses.
The concept of vaccination comes from the presence of an antigen from a harmful
substance that produces antibodies, a protein molecule by the body's immune response process.
In most standard vaccination, effectively killed or attenuated organisms, or parts of organisms is
introduced as antigens into the body to produce an immune response (Tulchinsky, & Varavikova,
2014). Scientists in China released the genetic sequence of the COVID-19 virus in January 2020,
which started research around the globe for a potential vaccine, including RNA-based vaccines
(U. S. National Library of Medicine, 2020).
Some pharmaceutical companies have used novel technologies to develop vaccines such
as BNT162b2 and MRNA1273 using a synthetic version of the mRNA that the coronavirus uses
and have received FDA’s Fast Track designation and have started phase three trial (U. S.
National Library of Medicine, 2020). These RNA vaccines can be constructed quickly using only
the pathogen’s genetic code. However, scientists have yet to determine how long the immunity
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produced by this vaccine can last (U. S. National Library of Medicine, 2020). There are some
differences between the conventional vaccines and RNA vaccine, as most COVID-19 vaccine
developments are RNA-based (see Table 7).
There is a great need to have an effective vaccine to combat COVID-19, but the
development must come with the caution of safety. Le et al. (2020) stated that the global effort
for research and development efforts for a COVID-19 vaccine in response to the pandemic is
unprecedented in the aspects of speed and scale, which represents a considerable change from
the traditional vaccine development pathway of five to ten years. Some of the issues to be
considered include the possible mutation of the COVID-19 virus (which may make the vaccine
ineffective), the side effects (which may be unknown), and the financial limitations to produce
enough quantity (for the global population). Other issues to be considered include educational
support to remove the myths associated with vaccination and trust in the vaccine's safety to
assure that the public will take the vaccine, primarily due to the speed and rush of its
development. Anderson et al. (2020) noted that one of the significant issues in this vaccine
development remains the participants' availability and site for phase three trial and
manufacturing enough vaccine for all when developed. All of the populations representative by
age, sex, race, and ethnicity need to be tested with adequate numbers.
Recommendations
The first recommendation is to fund the research for all COVID-19 treatments. Second,
establish and support strategies to increase more convalescent plasma donors. Third, create
equitable access, cost, and distribution of the COVID-19 medication and vaccine. And the fourth
is to mandate policies regarding vaccination to attend schools, including public and government
workplaces. Effective treatments for COVID-19 require more research and development, which
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needs to be funded. These treatments could be medications, vaccines, or convalescence plasma.
Collaborating with research institutes, individuals, organizations, government agencies, and
federal governments to develop strategies and raise funds for this research is needed.
Professional organizations and healthcare institutions should advance their convalescent donor
drive strategies to get more plasma with antibodies.
As efforts are being made to develop effective vaccines against COVID-19, measures to
minimize political influences and personal gains from affecting the approval, production, and
effective distribution of the vaccines when approved to the communities need to be considered.
Such measures could include making the vaccines free for all when it comes out, federal funding
to increases production, and a planned distribution guide to ensure fair distribution and vaccine
availability. Individuals such as Bill Gates have collaborated with pharmaceutical companies to
ensure safe development and availability of COVID-19 vaccines. Collaborating with more
individuals and private and public organizations will help to increase vaccine availability for all.
Consideration should be given to these five principle key factors: access, transparency, equity,
efficacy, and safety, to ensure trust and success in COVID-19 vaccination (ANA, 2020). Global
efforts should be directed towards providing vaccines to all, especially in countries that have
limited resources.
Testing
Testing plays an essential role in the effort to combat the spread of COVID-19. Two
types of testing (see Table 8) include a viral test called reverse transcriptase-polymerase chain
reaction (RT-PCR) test through nasopharyngeal swabs and saliva to identify current infections,
and antibody testing to identify evidence of the previous infection, which could be IgG, IgM, or
IgA. The RT-PCR test is the gold standard for COVID-19 testing, with an average sensitivity of
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97.2%, while the serological test has an average sensitivity of 84.5% for IgM and 91.6% for IgG
(Boger et al., 2020). While the CDC (2020e) recommends testing high-risk individuals as a
priority, expanding access to test to the public will be very beneficial as asymptomatic patients
contribute to a high level of community spread. The RT PCR-based diagnostic test takes 48
hours and more for results to be back (Younes et al., 2020), which creates delays in quarantine
and other treatment decisions such as elective surgery, and bed placement in healthcare
institution for inpatient admission. In reality, for many states, it takes 5-7 days for results to be
available due to limited resources for timely collection, analysis, and test reporting in the
laboratories.
Several studies have noted that although negative test results may be enough for low-risk
individuals, additional measures should be taken to protect against the spread of COVID-19 in
false-negative, asymptomatic high-risk individuals and populations (Furst, 2020; West et al.,
2020; Zitek, 2020)). It is important to note that a negative test may be a false negative or that the
individual is not infected at the time of the test but can still be infected. A positive test is highly
suggestive of having true COVID-19. This is significant because false-negative result carries
greater consequences of relaxing some individual’s perspective and personal prevention
strategies contributing to an increased spread.
Recommendations
The first recommendation is to fund the resources for testing and increasing the number
of tests performed daily through free testing for all. The second is to increase access to COVID19 testing in the community by implementing community-testing programs. To improve health
and healing, it is recommended that access to health care and health care services be expanded
for all. This expansion will include access to COVID-19 testing and testing sites targeting areas
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with increased disparities. Strategies to provide free treatment, testing, and prevention for all
should be firmly instituted and implemented. Such measures may include implementing a
community-testing program and increasing testing sites in the community. Funding for more
resources to collect, analyze, and report COVID-19 tests timely will help eliminate delays and
decrease spread in the communities from asymptomatic and pre-symptomatic individuals who
wait longer for their test results or may not even have access to testing.
Ritchie et al. (2020) stated that testing guides the COVID-19 pandemic, helping to
understand better how the virus is spreading to respond appropriately. As testing is increased,
infected individuals are identified. This helps guide interventions, and efficient allocation of
resources enables proper isolation of infected individuals and improves tracking and
quarantining of identified contacts. Some countries have implemented several ways to increase
testing that have been helpful in their approach to slow down the spread of COVID-19. As of
September 16, countries such as the United Arab Emirates and Denmark perform a high daily
testing rate (8.56 and 7.16, respectively) compared to the United States that performs 2.22 daily
tests per thousand people (Ritchie et al., 2020). Evidence has shown that some countries or
regions have slowed the spread of COVID-19 using large-scale testing and case isolation, as seen
in South Korea (Cherif and Hasanov, 2020) and a Veneto community in Italy (Zingales, 2020).
Since testing is beneficial, adopting and implementing these recommendations is
essential. These can be achieved through collaboration with professional organizations,
community groups, and lobbying specific organizations or individuals. Some local, state and
national organizations have staffed community-testing centers, as seen in some community
hospitals' effort to conduct community testing in some states, but more is still needed. There is a
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great need for more individual and organizational collaboration in funding to have COVID-19
testing sites and make testing easily accessible for all with timely turn-around for results.
Contact Tracing
The CDC has recommended contact tracing as a critical strategy for preventing the
continual spreading of COVID-19. Closely monitoring and examining family members can
achieve early prevention and control of COVID-19 infection and social contacts of COVID-19
patients, even if they do not have any symptoms (CDC, 2020a; Pan et al., 2020). Immediate
identification, self-isolation or quarantine, and monitoring of COVID-19 patients and their
exposed close contacts can break the chain of disease transmission, effectively preventing the
further spread of the virus. The CDC (2020a) stated that the steps of contact tracing are laborintensive and include: case investigation (identifying close contact of infected patients), contact
tracing (notifying the exposed contact), contact support (providing educational information and
resource support for the exposed contact), and self-quarantine (stay home and social distance for
14 days from exposure date). COVIDTracer, a new spreadsheet-based tool, allows for comparing
three different strategies used for contact tracing, and the CDC developed monitoring by public
health officials. This tool is very robust, with multiple stages, and requires training for effective
implementation. Some other digital applications have been developed but have not been
approved in some countries due to privacy concerns.
Recommendations
The recommendations include first to standardize and fund a national strategy for
surveillance and contact tracing. Second, fund, support and make manual contact tracing a
national strategy for infection control, including COVID-19. Contact tracing, a vital tool in the
epidemiology of COVID-19, has been widely implemented in some regions, countries, and states
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to identify the contacts of infected COVID-19 patients and properly quarantine them to slow the
spread. In some countries like Singapore, Taiwan, and Hong Kong, these containment measures
seem to have reduced the spread of local transmission and sustain it (Cowling and Aiello, 2020).
Several countries are using technology to conduct contacted tracing with promising results.
Countries like Iceland implemented the Running C-19 app. Australia uses the CovidSafe app,
New Zealand implemented the NZ COVID tracer app, and South Korea used multiple digital
means, including phone records, to trace contacts (Dayaratna et al., 2020).
Although these digital means come with their controversy of privacy issues, these
measures can be tailored to individual country's rules and regulations. Collaboration with
technology sectors is recommended to discuss and plan the possibility of an effective digital
method of contact tracing that will be nationally accepted considering privacy concerns. Some
states have started manual contact tracing, which is labor-intensive, and with limited funds,
paying for this labor remains a challenge. A situation exists where interstate travels with no
uniform contact tracing by all states, creates an ineffective and inefficient contact tracing effort
by the states that are doing it already. The current effort of manual contact tracing needs to be
funded and supported by the federal government, making it a national strategy for infection
control, including COVID-19. With the current challenge of unemployment in the country, an
efficient strategy will be to hire and train individuals, especially in the rural communities, and
get them in the workforce of a coordinated contact tracing system. This will provide job
opportunities and provide effective use of the unemployment fund while implementing an
effective strategy that has been proven to slow the spread of COVID-19.
The other two recommendations include first to implement enhanced public health
intervention such as isolation centers, especially in communities with a high risk of infection
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spread. Second, encourage the private sector to develop and support voluntary isolation centers.
Establishing temporary isolation centers for people with positive COVID-19 need to be
implemented, especially in communities with a high risk of infection spread. With an established
history of containment similarly done with infections such as tuberculosis and leprosy, countries
like Iceland and South Korea used these containment measures with good outcomes (Dayaratna
et al., 2020). Although interventions to mitigate the spread of COVID-19 should be implemented
for all, paying particular attention to hot spot areas by identifying contact and taking extra
measures to isolate or have them quarantine will be beneficial. Policymakers and legislators need
to adopt this containment measure to slow down the spread of COVID-19, especially in the
communities with a limited place for isolation. Lawmakers need to collaborate and lobby private,
and business sectors with space currently incurring significant setbacks such as the hotel and
cruise industries to provide designated space for less or no cost. Discussion with private and
government insurance branches for coverage of isolation services as in other medical treatments
is recommended as these measures come with a cost. These are strategies that can be kept in
place and ready in future public health emergencies.
Managing Stress, Mental Health, and Healthcare Access,
Several plans have been recommended by the CDC (2020f) to manage stress as well as
improve mental health and addiction services during this COVID-19 pandemic and beyond.
Some of the plans include increasing the availability and easy access to mental health services,
especially in the local and rural communities, providing telehealth services, and minimizing cost.
Other recommendations are listed below:
•

The provision and training of adequate mental health professionals and response staff
to provide triage, counseling, outreach, and education during a crisis or emergency.
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Establish and coordinate role partners such as community-based organizations in
mental health services during an emergency.

•

Develop templates and communication plan to ensure prompt communication of risk
for adequate follow-up and risk management.

•

Develop an appropriate triage system for connection and easy flow of mental health
services when needed.

•

Ensure an adequate plan for interpreter and translation services to accommodate the
diverse community.

•

Provide easily accessible and affordable mental health and addiction services within
the communities.

•

Train provider groups and community support workers, including school health
professionals and public health nurses, in the psychosocial consequences of
emergencies and disasters.

Recommendations
The recommendations are first to expand and improved access to mental health services by
investing in community programs and technology. Second, allocate funds to implement the
recommended plans to improve mental health and addiction services. Third, expand coverage
and reimbursement for mental health services from Medicare, Medicaid, and private insurance
agencies.
Meeting the demands of mental health care was a great challenge even before COVID19. More strain has been added to this aspect of wellbeing since the COVID-19 pandemic as
social structures, health systems, and the economies are significantly impacted. According to the
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UN director-general, there has been a significant impact on the wellbeing and mental health of
the society by the COVID-19 pandemic and recommends three critical actions:
•

The use of a societal approach to protect, promote, and care for mental health patients
entails the provision of widespread emergency mental health availability and
development of mental health services for future psychosocial support and support of
recovery from COVID-19.

•

Integrate mental health into youth entrepreneurship programs in the communities

•

Integrate digital technology into scalable models to deliver services and model
successful interventions that have been implemented in some countries (Rahman et
al., 2020).

Some examples of these actions were seen in countries like Colombia, India, and
Mozambique's digital tools to manage stress, anxiety, and depression among COVID-19
response frontline workers (Rahman et al., 2020). Family and community-based preventive
interventions have been used in countries like Sierra Leone. They have successfully reduced the
risk of mental health problems associated with displacement, socio-economic stress,
resettlement, and poor access to care (Rahman et al., 2020). Some of these interventions focus on
prevention and early identification of factors that contribute to mental health issues while
providing effective treatment intervention for mental health well-being.
With COVID-19 impacting communities facing health disparities and poor access to care,
digital technology to deliver the needed care has proven to be an effective strategy. This delivery
could be through the invention and use of digital applications that are user friendly and can
connect to the electronic health record to facilitate mental health service delivery. Some of the
proven ways to connect to the community and increase community programs that focus on
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mental health well-being collaborate with community organizations, investing in community
entrepreneurship, and mobilizing youth champions for effective youth programs. Establishing
community programs and technology innovations requires funding. Some of the ways to fund
these programs can be through lobbying and collaborations with organizations, churches, and
technology companies for support. Legislative support and buy-in for state and or federal
funding is also needed for a wide-scale approach.
Healthcare Access through Telehealth
Telehealth has contributed much to the continuity of care for patients during this COVID19 pandemic. Telehealth is an efficient and effective way to triage and provide timely medical
care to patients during this crisis moment (Lee et al., 2020). Telehealth can help maintain issues
with access and continuity of care for the patients, minimize the spread of COVID-19, optimize
in-person services, and provide maximum support for colleagues on the front line (Lee et al.,
2020). Patients could receive care without exposing themselves or their providers since the
provider uses the telephone or video. This system also helped reduce emergency room
congestion for less severe cases, as in-person care is limited to the most urgent patients.
To respond to COVID-19 and appropriately provide adequate and timely care to
Medicare beneficiaries during this pandemic, the Centers for Medicare and Medicaid
Services (CMS, 2020) expanded access to the telehealth method of providing care and services
with a full reimbursement. This expansion has helped increase patient access to the primary care
provider and specialty services and reduce exposure and spread of COVID-19, especially those
at high risk of complications from COVID-19. Under the 1135 waiver authority and Coronavirus
Preparedness and Response Supplemental Appropriations Act, CMS expanded the telehealth
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services temporarily to allow the exchange of medical information from one site to another using
electronic communications (CMS, 2020).
Recommendations
The recommendations include first to make the Medicare expansion of telehealth
permanent beyond the COVID-19 public health emergency. Second, extend telehealth coverage
for Medicaid and other private insurance holders. Policy barriers that limit treatment during the
COVID-19 crisis, such as limited telehealth eligibility, controlled substance prescriptions
restrictions, and limited access to emergency and essential healthcare services that have been
modified to improve care, should be made permanent. Telehealth has contributed to increased
access to healthcare services while minimizing patient and staff exposure; thereby, slowing the
community spread of COVID-19. To continue to improve patient's health outcomes, the use of
telehealth services needs to be made permanent.
In the present healthcare uncertainties, telehealth will benefit Medicare patients and help
eliminate barriers that affect healthcare access around the globe, especially in rural areas and
regions without adequate healthcare resources. Telehealth remains a possible approach to
overcoming healthcare barriers existing in the world where ethnic origin, socio-economic status,
and geographical locations determine community access to healthcare services (Eccles, 2012).
This approach has proven successful in India's countries, even before the COVID-19 pandemic
(Eccles, 2012). Lawmakers need to keep the Medicare expanded telehealth services permanent
and extend the telehealth coverage to Medicaid and other private insurance groups.
Safe Reopening of the Economy
Dangers faced by emotions, fear, apathy, and selfishness may hinder the guidelines and
regulations, although this is not justified. How to help develop individualized coping
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mechanisms to COVID-19 practices remains an area that needs further exploration as cities and
states begin their cautious phases of reopening. Consideration for reopening of schools,
businesses, bars and restaurants, recreational centers, theme parks, infrastructures, and travel,
requires that specific guidelines be followed to minimize the resurgence of COVID-19. While
there is an urgent need to reopen the economy, doing so in a way that will prevent the resurge of
infection and a subsequent second shutdown could prevent lasting and profound damage (Stock,
2020). Everyone should uniformly practice preventive measures such as mask-wearing in public,
social distance, and hand washing for public health safety.
Among the significant issues in the safe reopening of the economy is in reopening the
schools, which comes with numerous school levels. The utmost controversy is that there is no set
general standard when it comes to practices for school reopening, but instead, it depends on the
agreement of the individual schools and local government. Tria (2020) noted that reducing the
student-teacher ratio remains one of the challenges of school reopening, as schools will be faced
with a lack of space for classrooms and a lack of staff to run the school. Every learning
institution should plan to implement measures and policies for physical distancing, cleaning, and
wearing facemasks. Some schools in different countries that reopened have recorded a
resurgence in COVID-19. The inability to maintain social distancing and asymptomatic patients,
coupled with the fact that some school-age children will be cared for by adults has been
challenging. A standardized approach to preventive strategies is required with increased
surveillance, testing, and contact tracing for the safe reopening of schools and other economic
sectors.
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Recommendation
Establish a national standard for the safe reopening of schools for all education levels.
Based on the evidence, when adequately implemented, preventive strategies help to minimize the
spread of COVID-19 and need to be implemented and enforced uniformly in all public and
private schools. The board of education in the local, state and national government and private
sectors must come together and develop a uniform standard for safe school reopening with
defined strategies to ensure compliance. Some countries such as Israel, France, and South Korea,
issued a detailed guideline for school reopening, which addressed mask-wearing, social
distancing with class size, testing, contact tracing, sports, and school cleaning. In Taiwan, the
education ministry established a detailed general guideline to uniformly be implemented by all
schools combining numerous strategies that included containment and mitigation practices to
keep operating (Cheng et al., 2020). These include defining mask-wearing guidelines, class sizes,
school cleaning requirements, temperature checks, hand hygiene, proper ventilation, contact
tracing, quarantine, travel history, and modified classroom routines. Addressing safe reopening
issues at both local, state, and national levels and establishing a national framework that will
guide different schools as they reopen safely is needed and should be adopted.
Education and Creating Awareness
The knowledge of COVID-19 and strategies for protecting and preventing its spread is
essential as it continues to evolve. Local, state, and national health departments, public health
officials, providers, and other healthcare personnel should collaborate with the schools, public,
and other private and public agencies to create awareness regarding COVID-19 (Ashour et al.,
2020; Srivastava & Saxena, 2020). Rural communities, especially the vulnerable populations,
need to be educated on the use of PPE’s, the need for social distancing, hand washing, what to do
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if infected, when to seek medical help, the importance of influenza (flu) vaccine, and other
available options such as testing, contact tracing, and medical care. Myths surrounding COVID19 practices such a negative test means that one will not get COVID-19 or people wearing a
mask do not need to practice social distancing are inaccurate and need to be dispelled.
The public should be educated on the proper technique for mask-wearing and proper
handwashing to ensure adequate coverage of the nose and mouth, not to touch the inside of the
mask, and proper disposal of masks. The public should understand that wearing a mask by
everyone is more efficient in protecting everyone. The first wearer protects another, and another
wearing mask protects the first wearer as it contains the virus and prevents it from spreading to
one another. The public wearing a mask may become the face of a unified action to fight against
the common threat of COVID-19 and reinforce the importance of social distancing measures
(Javid et al., 2020). Education to explain the difference between isolation and quarantining (see
Table 3) is essential to slow the spread of COVID-19. Flu vaccine awareness is much needed and
advocating for all to take the flu vaccine should be the responsibility of all but more especially
for the health care professionals.
Recommendations
Teach infection prevention strategies at all school levels as part of the school curriculum
requirement. The global health community’s goal is to decrease the spread of infectious diseases
and flatten the curve's peak in any epidemic crisis. Public education regarding the various aspects
of disease transmission, preventive measures, and available treatment modalities will help
achieve this goal when implemented quickly. Continuous and constant reinforcements of these
preventive measures are needed to reduce the resurgence of COVID-19 as schools and other
private and public sectors reopens. The current surge in COVID-19 among youths is partly
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attributed to poor understanding and non-compliance to established preventive strategies. Efforts
should be made towards implementing some initiatives that can continuously keep youths
informed and boost compliance. A public fact sheet (see Figure 10) will help create awareness on
keeping safe while dealing with COVID-19 and ways to prevent its spread. In contrast, the
provider fact sheet (see Figure 11) will center on the prevention of COVID-19, treatment
approach, mental health consideration, and patient education. Transparent and careful
communications and awareness of the preventive measures will help promote public engagement
and improve compliance.
The other recommendations include first to provide incentives for flu vaccine
administration in the fee for the performance module of healthcare reimbursement. Second,
implement and fund educational outreach and mobile flu vaccine clinics, especially in rural
communities. Third, businesses, schools, healthcare facilities, and colleges should mandate flu
vaccination. Finally, healthcare reimbursement and insurance agencies should offer discount
rates if individuals or groups take influenza vaccines.
Influenza season has always been a challenging moment in infection control, with many
individuals still hesitant in taking the flu vaccine. Most people have also expressed the same
hesitancy for the COVID-19 vaccines that are being developed. Looking at the statistics in the
past influenza season (see Table 9), it is evident that there is a great need for education and
advocacy to increase the acceptance of flu vaccine for population health. COVID-19 is still
evolving, and healthcare is faced with the unknown of dealing with influenza and COVID-19.
The impact has been speculated to be devastating if people will not take the flu vaccines.
Strategies such as massive educational outreach and mobile community flu clinics will increase
understanding, access, and flu vaccination availability to the public. Initiatives that will increase
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education and provision of flu vaccines to patients, such as providing an incentive for providers
that document their education and providing flu vaccines to their patients, will increase
compliance similar to the strategy used with smoking cessation. Businesses, schools, healthcare
facilities, and colleges should mandate flu vaccination, just like other vaccinations such as
chickenpox, meningitis, and MMR. Healthcare reimbursement and insurance agencies should
offer incentives to individuals and groups that received the flu vaccine in the form of reduced
premium rates or reduced service fees.
Long-term policies, sustainable measures, and structural measures must extend beyond
the current COVID-19 crisis. Such measures include more vital nutritional support, universal
basic income, more comprehensive reentry support, and job guarantees that will improve
population safety and stability during this COVID-19 crisis and beyond (The Heartland Alliance,
2020). The needs of the ethnic and racial minorities, the poor and underprivileged, and other
vulnerable populations should be monitored, addressed, and protected.
Dissemination Plan
This project will be reviewed by the course professor, university peers, the DNP student
preceptor, and an academic mentor before dissemination. The dissemination will start in the
community and include religious organizations, department stores, schools, park district
recreational centers, and colleges using flyers, fact sheets, and posters. The project will also be
disseminated in the healthcare organization using PowerPoint, where the leadership teams and
front-line staff will be invited to a town hall meeting. Dissemination to the local, state, and
national legislators through email or online platforms will also be done at the end of the project.
Poster presentations in one of the local nursing organizations (Nigerian Illinois Nurses
Association) with national affiliation will be done through Zoom and podium presentations
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during face-to-face events. Poster and podium presentations will help to reach the vast majority
of people. On the national level, an abstract will be submitted to the 28th National EvidenceBased Practice Conference, University of Iowa Health Care, held on April 14 and 15, 2021. If
accepted, it will display a poster presentation for viewing during the event. An abstract will also
be submitted to the Illinois Society for Advanced Practice Nursing (ISAPN), American Nurses
Association conference, and Sigma Theta Tau International Honor Society of Nursing, with a
full project presentation in the future.
Other areas include dissemination to policymakers as well as government and private
agencies through emails, journals, and other online platforms. The publication will be done
through the nursing journal, such as the American Journal of Nursing, because this is one of the
broad-based and most honored nursing journals that provide peer-reviewed and evidence-based
articles to the vast majority of the audience. This project's full text will be disseminated through
submission to the Scholarship and Open Access Repository (SOAR) and Virginia Henderson
International Nursing Library for global dissemination.
Conclusion
The unprecedented threats brought by COVID-19 have led to some strategic responses by
the federal, state, and local governments and communities to mitigate health and economic
unrest. Covid-19 is still an evolving infection with no established medical cure yet available.
Efforts to end this pandemic lie in compliance with preventive measures, the development, and
availability of effective treatment, and a COVID-19 vaccine. The devastating effect of the
COVID-19 pandemic has affected the global community slowing the business and economic
sectors, schools, healthcare services, and individual living situations. The review of available
evidence on COVID-19 revealed some preventive measures that could help prevent the spread of
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COVID-19 and minimize its impact on the global communities. Preventive measures should be
widely encouraged at all levels of human operations and measured to ensure that awareness and
compliance are embraced with all seriousness. The fact sheets were used to disseminate the
identified practices to help reduce the spread of COVID-19. A global approach to preventive
measures, treatment, and vaccines is needed to deal with the COVID-19 pandemic.
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Table 1.
Some COVID-19 Signs and Symptoms, and Complications
Signs and Symptoms
Fever of >100.4F

Complications
Pneumonia
Pulmonary edema, Acute respiratory failure

Dry or productive Cough

Elevated liver enzymes causing acute liver

Shortness of breath, Wheezing, Hypoxia

Acute respiratory distress syndrome

Chest distress, dysrhythmia

Acute kidney injury

Myalgia (body aches)

Acute coronary syndrome with elevated troponin

Nasal congestion and or rhinorrhea

Heart failure

Anosmia (loss of smell)

Myocarditis and Myocardial injury

Ageusia (loss of taste)

Arterial and venous thromboembolism

Loss of appetite

Prothrombotic coagulopathy

Sore throat, pharyngeal pain

Macrophage activation syndrome

Nausea, Vomiting, Diarrhea

Cytokine storm

Abdominal pain

Shock and multi-organ dysfunction

Lassitude or weakness, fatigue

Impaired consciousness

Reduced alertness and or mobility

Acute cerebrovascular disease

Headache, Delirium, confusion

Cutaneous manifestations of popular and reddish
lesion like chilblains seen on the toes (COVID
toes), soles, fingers or heel.

In children: Kawasaki-like disease

Lingering memory issues, fatigue, and

symptoms: non-purulent conjunctivitis,

debilitating pain for some patient that have

polymorphic rash, mucosal changes, and

recovered from COVID-19 has been reported.

swollen extremities
-Multisystem inflammatory syndrome in
children (MIS-C)
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Table 3.
COVID-19 Quarantine vs Isolation
Isolation
Symptomatic and positive asymptomatic
individuals are kept away from others even in
their homes.

Quarantine
Individuals who are in close contact
(exposed) with COVID-19 positive individual
is kept away from others
Exposure means: Being within six feet of
contact for 15 minutes or more, direct contact
without proper PPE as in providing care,
sharing eating or drinking utensils, or being
sneezed or coughed at or exposed to COVID19 droplets.

Stay home for 10 days from date of onset of
symptoms, and 24 hours fever free without
fever reducing agents, and with improved
symptoms.

Stay home for 14 days from the date of your
last exposure.

Stay home for 10 days from the date of your
last positive test.

Check temperature two times a day and watch
for COVID-19 symptoms (Should be <100.4).

In a multi-living situation, stay away from
As much as possible stay away from people
others in a designated "sick room" with a
who have a higher risk of having poor
separate bathroom if possible.
outcomes if they contract COVID-19.
(Center for Disease Control and Prevention, 2020d; Srivastava, & Saxena, 2020)

COVID-19: Best Practices and the Way Forward
Table 4.
Mask Overview
Type of Mask
N95

Description
A respirator mask that offers more protection than a surgical mask.
It can filter out both large and small particles when the wearer inhales.
Designed to block 95% of very small particles
Some N95 masks have valves that make them easier to breathe through.
With this type of mask, unfiltered air is released when the wearer exhales.
-Fit testing recommended for the proper size.

Surgical mask

A loose-fitting disposable mask that protects the wearer's nose and mouth.
Filters out large particles in the air such as droplets, splashes, and sprays
that may contain germs

Cloth mask

To cover the wearer’s mouth and nose but not certain if it offers protection
or at what level. Need to be washed daily.

Dust mask

Filters dust particles and mostly for occupational work

(Osborn, 2020)
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Table 5.
Airborne and Droplet Isolation
Airborne Precaution
Used when the transmission is by inhaling
viral particles floating freely in the air or
aerosol.

Droplet Precaution
Used when the transmission is by contact
with droplet particles.

Aerosols: Tiny particles that can be
suspended in the air and float for a longer
period, leading to airborne transmission.

Droplets: Mucous or saliva particles large and
heavier than air are expelled, falling towards
the ground and immediately come in contact
with another person's mouth, nose, the
mucous membrane of eyes, or on surfaces.

Airborne: Virus droplet particles that are
small enough to float in the air for a longer
period.

Precautions include wearing a surgical mask,
eye covering or face shield, gloves, and gown,
and isolating the patient in a room.

Because the COVID-19 viral particles
expelled can be aerosol or large enough to be
droplets, precaution include wearing an N95
or higher-level respirator, eye covering or
face shield, gloves, and gown, and isolating
the patient in a negative
pressure airborne infection isolation room.
(Bahl et al., 2020; Center for Disease Control and Prevention, 2020d)
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Table 6.
COVID-19 Supportive Treatment
Problem
Fever

Supportive treatment
Use antipyretics alongside other fever-reducing measures.

Dry cough

Provide comfort measures to relieve cough may be needed such as small
sips of water, although relatively low dose opioids such as oral morphine
may help reduce cough alongside treatment for breathlessness

Thrombotic event
prophylaxis

Administer low-molecular-weight heparin in the early phase of COVID19 treatment for a positive effect on thrombosis prevention as well as
reducing systematic and pulmonary inflammation.

Bacterial Coinfection

Use antibiotics but in a situation where bacterial co-infection cannot be
ruled out in COVID-19 patients, the use of empirical antibiotics was
recommended for mild cases and a broad-spectrum antibiotic coverage is
suggested for severe cases.

Inflammation

Corticosteroids (prednisone, methylprednisolone) and Dexamethasone
are potent anti-inflammatory drugs that have been used.

Hypoxia

Oxygen therapy is given through a nasal cannula to correct hypoxemia
and improve oxygenation. Some severe cases may require a nonrebreather mask, a Bi-pap machine, or possibly ventilator support.

Anxiety

Anxiety-related to fear, social and family isolation, and breathlessness
may be present in some patients, studies have shown that nonpharmacological methods such as breathing exercise and relaxation
therapy are helpful in mild cases.
(Bajwah et al., 2020; Lai et al., 2020; Rizk et al., 2020; Thachil, 2020)
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Table 7.
Comparison of RNA and Some Standard Vaccines
RNA Based Vaccine
Synthetic

Some Standard Vaccine
Inactivated pathogen

Uses pathogen’s genetic code

Uses the weakened form of the virus

Quicker to construct
(U. S. National Library of Medicine, 2020)

Takes longer to develop
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Table 8.
COVID-19 Testing
Viral test- Reverse transcription-polymerase
chain reaction (RT-PCR).

Serological tests
(Binding antibody detection test)

Nasal Swab and Saliva
Sputum specimen sensitivity from
nasopharyngeal swab remains at an average
of 97.2%. Result turn around takes up to 48
hours and more.
Identifies the RNA of COVID-19 virus

Blood/Saliva: Laboratory-enzyme
immunoassays (EIA) and rapid, point of care
(POC) tests (blood which can be by finger
stick or saliva). Can be collected easily from
the blood draw.
Detects antibodies IgG, IgM, and IgA.
IgG- remain detectable for months or years.
The average sensitivity of 91.6%.

The RT-PCR-based test is the gold standard
for COVID-19 diagnostic

IgM- for recent infection as it may disappear
weeks to months following infection. The
average sensitivity is 84.5%.
IgA- important for mucosal immunity and
can be detected in mucous secretions like
saliva in addition to blood

More prone to deterioration during sample
collection, preparation, transport, storage,
and testing compared to serological testing.
Negative result does not mean the absence of
COVID-19 but simply mean that there is a
probability that the individual is not infected
at the time of sample collection and can still
be infected

Not be enough to diagnose COVID-19,
combine with molecular techniques for a
valuable diagnostic result.
Can detect past infection providing better
information on disease prevalence in the
population.
Fewer variations compared to nasopharyngeal
specimens because antibodies are usually
homogeneously dispersed in the blood.

Slow antibody response to SARS-CoV-2 virus,
as they may not be detectable until three days
from symptom onset or at least 7–10 days after
infection
Not designed to detect individuals in the early
stages of COVID-19 infection.
Unreliable for the detection of acutely infected
individuals as less than 40% of infected
individuals are seropositive (IgM/IgA) in the
first seven days.
(Boger et al., 2020; Center for Disease Control and Prevention, 2020e; Younes et al., 2020).
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2019-2020 US Flu Season Data
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Figure 1.
Global Trend of COVID-19 from February to September 2020
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Figure 2.
Death Rate by WHO Region as of October 17, 2020
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Figure 3.
COVID-19 Confirmed Cases by WHO Region from February to September 2020
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Figure 4.
COVID-19 Deaths by WHO Region from February to September 2020
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Figure 5.
COVID-19 Trend in Confirmed Cases: Top 12 Countries from February to September
2020
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Figure 6.
COVID-19 Trend in Most Deaths: Top 12 Countries from February to September 2020
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Figure 7.
COVID-19 Coinfection Respiratory Pathogens
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Figure 8.
Big Picture Illustration
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Figure 9.
Types of Immunity
Active Immunity: Antigen exposed to
body to generate an adaptive
immune response. Takes days/weeks
for response but lasts longer up to
life long.

Passive Immunity: IgG antibodies
provided to the body to protect
against infection. Response ie
immediate but lasts shorter for
several weeks to upt to four months.

Natural Active
Immunity: Recovery
from wild infection

Natural Passive
Immunity; transfer
from mother to
newborn through
placenta

Acquired Active
Immunity: From
vaccines

Acquired Passive
Immunity: Recieving
serum from immune
individuals

(Center for Disease Control and Prevention, 2020d)
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Figure 10.
COVID-19 Public Fact Sheet
COVID-19 PUBLIC FACT SHEET
COVID-19: An infection caused by
Nova coronavirus (SARS-CoV-2)

How to Slow the Spread of COVID-19

-Avoid large crowd gatherings
How does COVID-19 spread?
Coughing/sneezing/contaminated
surfaces/Aerosol producing activities

What are the symptoms? Appears
two to 14 days after exposure
FEVER

DIFFICULTY BREATHING

COUGH

LOSS OF TASTE/SMELL

MUSCLE ACHES

SEVERE ILLNESS

How to Slow the Spread of COVID-19

-Stay home if you are sick

Soap and water Hand Sanitizer
-Wash hands frequently

-Avoid touching face with unwashed hands

-Wear mask in public

-Cover your cough and sneeze/ use your
elbow

-Clean and disinfect high touch surfaces

-Call before visiting your healthcare
provider
-Get adequate sleep, rest, and eat a wellbalanced meal
-Maintain 6 feet social distancing

For More Information See CDC.gov
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Figure 11.
COVID-19 Healthcare Provider Fact Sheet
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Appendix A.
Evidence Review Table
Citation

Themes

Outcome and Key Findings

Design, Level,
Quality Grade

Ahmed, S., Quadeer, A.,
& McKay, M. (2020).

Vaccine
production

Preliminary identification of potential
vaccine targets for the COVID-19
coronavirus.

Level III, Grade B.

Anderson, Heesterbeek,
Klinkenberg, &
Hollingsworth (2020).

Prevention
strategies.
Vaccine
limitation

A personal effort will help in the
prevention of the spread of COVID-19.
The big issue in vaccine development
remains the site for phase three trial and
manufacturing at the required scale

Supplemental article
from Elsevier Public
Health Emergency
Collection.

Ashour, Elkhatib,
Rahman, & Elshabrawy,
(2020).

Prevention
strategies and
Testing

Hand washing and a quick diagnostic test.
How treatment and preventive strategies
are implemented determines the future of
COVID-19.

Case report article, level
4, quality grade B

Bajwah, Wilcock,
Towers, Costantini,
Bausewein, Simon,
Bendstrup, …
Higginson, (2020).

Supportive
treatment

There is a moral obligation to provide
expert symptomatic and supportive
treatment for frail patients with multiple
comorbidities to prevent avoidable
suffering.

Supplemental review
material

Canadian Centre for
Occupational Health and
Safety. (2020).

Hand washing

Hand washing as a preventive measure in
controlling infections

Reputable government
agency website

Center for Disease
Control and Prevention
(CDC), (2020).

Mental health
and addiction
problems.

Disease outbreaks can increase stress that
ranges from stress regarding personal
health and the health of the loved ones,
eating and sleeping pattern changes with
poor concentration. Increasing stress also
causes worsening of mental health
conditions and increased use of alcohol,
tobacco, and recreational drugs.

Reputable government
agency website

Center for Disease
Control and Prevention.
(2020).

Prevention
strategies

To reduce the spread and prevent
COVID-19, it is recommended that every
individual, community, and the
population at large follow certain
guidelines.

Reputable government
agency website

Center for Disease
Control and Prevention.
(2020).

COVID-19
Testing

Two types of testing, viral test (to identify
current infection), and antibody testing
(to identify the previous infection). Local
and state health departments and
providers should make decisions about
whom to test. Everyone regardless of the
test result should take preventive
measures.

Reputable government
agency website

Center for Disease
Control and Prevention.
(2020).

Vaccine trials

No vaccine currently for COVID-19,
vaccine trial is still in progress.

Reputable government
agency website
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Fogarty, Townsend,
Cheallaigh, Bergin,
Martin‐Loeches,
Browne, Bacon, …
O'Donnell, (2020).

Supportive
treatment
(Thromboembol
ic complication
of COVID-19
and heparin
treatment)

Administration of low-molecular-weight
heparin in the early phase of COVID-19
treatment may have a positive effect on
thrombosis prevention as well as limiting
viral infection and reducing systematic
and pulmonary inflammation.

Retrospective study

Food and Drug
Administration (2020).

COVID-19
testing

Authorized the first diagnostic test with a
home collection option for COVID-19
using home-collected saliva samples

Reputable government
agency website

Furst, (2020)

COVID-19 test
result

The sensitivity and overall test
performance characteristics of RT-PCR
testing are not yet clearly and consistently
reported. This can create a false sense of
security with a false negative result.

Peer review medical
journal article from a
reputable healthcare
organization

Illinois Department of
Public Health

Prevention
strategies

Avoid close contact by staying at home as
much as possible, social distance, and
wear masks in public.

Reputable government
site

Javid, Weekes, &
Matheson, (2020).

Prevention
strategies

Social distancing and wearing a mask to
prevent COVID-19 spread

Johns Hopkins
Medicine. (2020).

Prevention
strategies

Avoid close contact by staying at home as
much as possible, and social distancing.
Cover cough and sneezes and wear
masks, clean and disinfect frequently
touched surfaces, and wear appropriate
PPE

Grey literature from a
reputable healthcare
organization

Lai, C., Wang, C., &
Hsueh, P. (2020).

Supportive
treatment
(Antibiotic
treatment of coinfection in
COVID-19
patients)

There is a possible bacterial co-infection
among COVID-19 patients but in a
situation where bacterial co-infection
cannot be ruled out in COVID-19
patients, the use of empirical antibiotics
was recommended for mild cases and a
broad-spectrum antibiotic coverage is
suggested for severe cases.

A systematic review of
cross-sectional studies

Le, Andreadakis,
Kumar, Roman,
Tollefsen, Saville, &
Mayhew, (2020).

Vaccine
development

The global effort for R&D for COVID-19
vaccine development in response to the
pandemic is unprecedented in the aspects
of speed and scale which represents a
huge change from the traditional vaccine
development pathway of five to ten years.

Prospective study

Lodigiani, Lapichino,
Carenzo, Cecconi,
Ferrazzi, Sebastian,
Kucher,
… Barco, (2020).

Supportive
treatment (Use
of heparin in a
hospitalized
adult patient)

Administration of low-molecular-weight
heparin in the early phase of COVID-19
treatment may have a positive effect on
thrombosis prevention as well as limiting
viral infection and reducing systematic
and pulmonary inflammation.

Retrospective cohort
study

Mayo Clinic. (2020)

Plasma
treatment trial

Use of ABO compatible convalescent
plasma treatment where the plasma of a
person that has recovered from laboratory
documented infection with SARS-CoV-2
is in the trial phase. The plasma from a
recovered patient is believed to contain

Grey literature from a
reputable healthcare
organization
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antibodies that will fight against the
COVID-19.
National Institutes of
Health (2020);
Center for Disease
Control and Prevention.
(2020).

Treatment
guideline,
antiviral, and
immune-based
therapy trial.

Antiviral medication-on trial phase.
Immune-based therapy 1) Convalescent
Plasma and Immune Globulins), 2)
Interleukin-6 Inhibitors- Both under
evaluation.
Antithrombotic therapy-Recommended
for prevention of venous thromboembolic
events in adult hospitalized patients per
standard.

Reputable government
agency website

Pan, Chen, Xia, Wu, Li,
Ou, Zhou, & Liu, (2020)

Contact tracing

Asymptomatic family members and close
contact of infected individuals can be
spreading the virus.

Observatory study,
evidence level III,
quality grade B.

Srivastava, & Saxena,
(2020).

Prevention
strategies, and
vaccine trial
progress

COVID-19 virus is a person-to-person
transmission. The precautionary measures
and efficient health response from
governments, healthcare personnel, and
the public can only prevent COVID-19
infection from spreading. different
vaccine trials are in progress.

Journal review

Thachil, (2020).

Supportive
treatment (Use
of lowmolecularweight heparin)

Administration of low-molecular-weight
heparin in the early phase of COVID-19
treatment may have a positive effect on
thrombosis prevention as well as limiting
viral infection and reducing systematic
and pulmonary inflammation.

Retrospective cohort
study

Tulchinsky, T. H., &
Varavikova, E. A.
(2014).

Vaccine and
plasma
treatment trials

Immune-based therapy and development
of vaccines for COVID-19. For vaccines
development, effectively killed or
attenuated organisms, or parts of
organisms are introduced as antigens into
the body, which response by producing
antibodies as active acquired immunity.

Evidence level III,
quality grade B.

West, Montori,
Sampathkumar, (2020).

COVID-19
testing and the
false negative
result

This study added that the false-negative
result carries great consequences of
relaxing personal prevention strategies
and increasing the spread of COVID-19
especially among asymptomatic people,

Expert correspondence
from a reputable
healthcare organization.

World Health
Organization

Prevention
strategies

Some simple precautions can help in
preventing the spread of COVID-19

International healthcare
agency site

Zhang, Zhao, Zhang,
Wang, Li, Liu, Wang, …
Zhang, (2020).

Supportive
treatment (Antiinflammation
therapy in
COVID-19
patients)

The use of anti-inflammation therapy
initiated at the right time is very
important to achieve the most favorable
effects.

Retrospective
observational study

Zitek, (2020).

COVID-19
testing

Recommended the appropriate use of
testing for COVID-19 and not overrelying on the test result. RT-PCR
nasopharyngeal swab test that is negative
is insufficient to rule out COVID-19.

Evidence level 1, quality
grade A
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Legend: RT-PCR-Reverse transcriptase-polymerase chain reaction; R&D-Research and
development
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